Myriad Genetics to Acquire Diagnostic Assets from Intermountain Precision Genomics
Myriad Genetics will acquire Intermountain Precision Genomics’ Precise Tumor Test, the Precise Liquid Test, and a CLIA-certified laboratory.
Read MorePosted by Andy Lundin | Jan 19, 2024 | Company News |
Myriad Genetics will acquire Intermountain Precision Genomics’ Precise Tumor Test, the Precise Liquid Test, and a CLIA-certified laboratory.
Read MorePosted by Andy Lundin | Jan 17, 2024 | Unknown Origin & Other Cancer Types |
Researchers invented a new test that uses a small brush to allow dentists to screen for the most common form of oral cancer.
Read MorePosted by Andy Lundin | Jan 12, 2024 | Cardiovascular |
The biomarkers may help more quickly predict cardiomyopathy in high-risk, asymptomatic childhood cancer survivors.
Read MorePosted by Andy Lundin | Jan 10, 2024 | Womens Health |
A noninvasive approach using leftover culture media could help doctors better predict success of in-vitro-fertilization
Read MorePosted by Andy Lundin | Jan 9, 2024 | Leukemia |
An AI-based solution may help predict various genetic features based on microscopic images of bone marrow smears to improve AML diagnosis.
Read More